Replimune/REPL

$8.97

4.18%
-
1D1W1MYTD1YMAX

About Replimune

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Ticker

REPL

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Coffin

Employees

284

Headquarters

Woburn, United States

Replimune Metrics

BasicAdvanced
$505.22M
Market cap
-
P/E ratio
-$3.16
EPS
1.22
Beta
-
Dividend rate

What the Analysts think about Replimune

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 9 analysts.
51.17% upside
High $19.00
Low $10.00
$8.97
Current price
$13.56
Average price target

Replimune Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
-
Net income
$-51.1M
-14.83%
Profit margin
0%
-

Replimune Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.99%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.74
-$0.75
-$0.90
-$0.77
-
Expected
-$0.67
-$0.84
-$0.86
-$0.93
-$0.79
Surprise
9.83%
-11.14%
5.18%
-16.99%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Replimune stock

Buy or sell Replimune stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing